Aytu BioScience Inc Cash Flow Conversion Efficiency
Aytu BioScience Inc cash flow conversion efficiency. Based on the latest financial reports, Aytu BioScience Inc (AYTU) has a cash flow conversion efficiency ratio of -0.119x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.18 Million) by net assets ($35.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aytu BioScience Inc (2007–2025)
Cash flow conversion efficiency of Aytu BioScience Inc from 2007 to 2025. This chart illustrates how Aytu BioScience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AYTU stock price and chart for real-time trading data and today's change.
Aytu BioScience Inc Cash Flow Conversion Ratio Explained
Aytu BioScience Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aytu BioScience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aytu BioScience Inc ranked by their cash flow conversion efficiency. Also see Aytu BioScience Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Korean Drug Co. Ltd
KQ:014570
|
0.024x |
|
VACCITECH (SP.ADR)/1
F:2AB
|
-0.051x |
|
Pure Hydrogen Corporation Ltd
AU:PH2
|
-0.252x |
|
CU Medical Systems Inc
KQ:115480
|
-0.030x |
|
Zuleika Gold Ltd
AU:ZAG
|
0.144x |
|
Food and Drinks Public Company Limited
BK:F&D
|
0.004x |
|
MegaMD Co. Ltd
KQ:133750
|
-0.005x |
|
Zee Learn Limited
NSE:ZEELEARN
|
0.024x |
Annual Cash Flow Conversion Efficiency for Aytu BioScience Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Aytu BioScience Inc from 2007 to 2025. Review Aytu BioScience Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $18.97 Million | $-1.94 Million | -0.102x | -103.94% |
| 2024-06-30 | $27.72 Million | $-1.39 Million | -0.050x | +61.57% |
| 2023-06-30 | $39.36 Million | $-5.13 Million | -0.130x | +79.97% |
| 2022-06-30 | $44.31 Million | $-28.82 Million | -0.651x | -244.67% |
| 2021-06-30 | $137.57 Million | $-25.96 Million | -0.189x | +36.80% |
| 2020-06-30 | $95.02 Million | $-28.37 Million | -0.299x | +84.70% |
| 2019-06-30 | $7.09 Million | $-13.83 Million | -1.951x | -64.34% |
| 2018-06-30 | $13.42 Million | $-15.94 Million | -1.187x | +65.66% |
| 2017-06-30 | $4.00 Million | $-13.83 Million | -3.458x | -227.19% |
| 2016-06-30 | $10.09 Million | $-10.66 Million | -1.057x | -148.75% |
| 2015-06-30 | $15.62 Million | $-6.63 Million | -0.425x | +58.54% |
| 2014-06-30 | $5.37 Million | $-5.50 Million | -1.025x | -401.27% |
| 2013-06-30 | $-110.86K | $-37.70K | 0.340x | -37.35% |
| 2012-06-30 | $-69.72K | $-37.85K | 0.543x | -70.19% |
| 2011-06-30 | $-35.59K | $-64.82K | 1.821x | +133.46% |
| 2010-06-30 | $-55.61K | $-43.38K | 0.780x | -77.28% |
| 2009-06-30 | $-13.58K | $-46.63K | 3.433x | +298.92% |
| 2008-06-30 | $25.96K | $-44.80K | -1.726x | -16.26% |
| 2007-06-30 | $18.81K | $-27.92K | -1.484x | -- |
About Aytu BioScience Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release o… Read more